Here, the duration (associated with disease onset and clinical status at initiation of SMN-augmenting therapy) and magnitude of SMN deficiency (associated with SMN2 copy number) appear to be significantly associated with developmental outcomes, with SMN2 copy number the strongest biological modifier of development in children with SMA. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.